Pharma Sector Pullback: CMBI attributes the recent pullback in the pharmaceutical sector to the rebalancing of valuations and expectations, which is expected to create better investment opportunities in the future.
Focus on Innovative Drugs: Looking towards 2026, CMBI emphasizes the importance of clinical progress and data realization of overseas pipelines as a key catalyst for growth in the long term.
Conservative Positioning Strategy: CMBI plans to adopt a more conservative investment strategy while seeking opportunities in undervalued stocks, recommending specific companies for investment.
Stock Recommendations: The report includes recommendations to buy stocks such as 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM, along with their respective short selling data and ratios.
Wall Street analysts forecast 01177 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01177 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 01177 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01177 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 7.110
Low
Averages
High
Current: 7.110
Low
Averages
High
G Sachs
G Sachs
Neutral
maintain
$63.3
Al Analysis
2025-11-11
Reason
G Sachs
G Sachs
Price Target
$63.3
Al Analysis
2025-11-11
maintain
Neutral
Reason
The article provides a list of stocks with their current prices, short selling data, and analyst ratings. All the listed stocks have a "Buy" rating, indicating that analysts believe these stocks are a good investment opportunity. The reasons for the "Buy" ratings are not explicitly stated in the provided text, but the presence of short selling data and the ratios may suggest that analysts see potential for price recovery or growth despite current short selling pressures. Additionally, the mention of "Order Momentum Remains Strong" for WUXI XDC implies that there is positive sentiment regarding its future performance, even though it has a neutral rating from G Sachs.
Guotai Junan
Buy
initiated
HKD10
2025-09-30
Reason
Guotai Junan
Price Target
HKD10
2025-09-30
initiated
Buy
Reason
The analyst rating from Guotai Junan for SINO BIOPHARM is a Buy, with a target price of HKD10. The reasons for this rating include:
1. Enhanced Innovation Capabilities: SINO BIOPHARM has improved its ability to innovate, which positions it well in the competitive healthcare sector.
2. Global Layout: The company has established a global presence, which can enhance its market opportunities and growth potential.
3. Improved Capital Market Sentiment: There has been a rebound in investment sentiment within China's healthcare sector, benefiting companies like SINO BIOPHARM.
4. Strong Market Position: As one of China's largest and most well-developed drug makers, SINO BIOPHARM has significant scale, financing capabilities, and commercial infrastructure.
5. Acquisition Potential: The company is well-positioned to acquire promising local biotech firms, which can accelerate the development and commercialization of new assets.
These factors collectively contribute to a positive outlook for the company's earnings and growth prospects in the coming years.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01177
Unlock Now
BOCI
Buy
maintain
2025-08-20
Reason
BOCI
Price Target
2025-08-20
maintain
Buy
Reason
BOCOMI
Buy
maintain
$8
2025-08-20
Reason
BOCOMI
Price Target
$8
2025-08-20
maintain
Buy
Reason
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
